Clinical Trials
43 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05136196 2026-05-19
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04708418 2026-05-14
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01989585 2026-05-13
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02298959 2026-05-13
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05896839 2026-05-13
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT05764395 2026-04-27
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Vanderbilt-Ingram Cancer Center
Phase 2 Active not recruiting
NCT04557956 2026-04-02
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03276832 2026-03-19
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT05098210 2026-03-12
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT05393713 2025-12-03
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study
Mayo Clinic
Phase 1 Terminated
NCT07155317 2025-11-12
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
Emory University
Phase 2 Recruiting
NCT00386906 2025-05-07
Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03412058 2025-02-20
CHECK'UP
UNICANCER
Phase NA Active not recruiting
NCT03757689 2025-02-11
Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma
Abramson Cancer Center at Penn Medicine
Phase 2 Active not recruiting
NCT01902173 2025-01-14
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02595866 2024-08-09
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT02977052 2023-11-15
OpACIN-neo
The Netherlands Cancer Institute
Phase 2 Unknown
NCT05906277 2023-06-15
Melamoma4p
Regina Elena Cancer Institute
Phase NA Unknown
NCT02414750 2022-11-30
REPOSIT
Netherlands Working Group on Immunotherapy of Oncology
Phase 2 Terminated
NCT00945269 2022-11-15
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01328535 2020-10-22
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Mayo Clinic
Phase 2 Completed
NCT01336985 2019-12-17
Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02654821 2018-11-02
TCR
The Netherlands Cancer Institute
Phase 1/2 Unknown
NCT00568763 2018-10-31
Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma
Mayo Clinic
Phase 1 Completed
NCT00715793 2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2 Completed
NCT02625337 2017-09-15
IMPemBra
The Netherlands Cancer Institute
Phase 2 Unknown
NCT00871481 2017-04-19
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00553306 2017-02-15
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00705640 2016-12-16
Mel48
University of Virginia
Phase 1 Completed
NCT01316692 2016-05-30
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00661336 2015-03-13
A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma
Duke University
Phase 1 Withdrawn
NCT00462280 2014-10-31
Lovastatin in Treating Patients At High Risk of Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00824889 2014-08-29
Exploratory Study of Natural Killer Cells in Human Skin
Assistance Publique Hopitaux De Marseille
Phase NA Completed
NCT00391300 2013-12-18
Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00466687 2013-07-22
Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT00438984 2012-03-16
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT01106235 2011-12-21
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT00602199 2011-05-16
ABT-510 in Treating Patients With Metastatic Melanoma
Mayo Clinic
Phase 2 Completed
NCT00811759 2010-10-07
Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma
National Cancer Institute (NCI)
Phase 1/2 Unknown